In a press release dated March 2nd, 2026, AIM ImmunoTech Inc. disclosed a partnership with the PPD™ clinical research unit of Thermo Fisher Scientific to develop a Phase 3 clinical trial for their drug Ampligen. This trial aims to explore the efficacy of Ampligen in treating advanced pancreatic cancer. AIM ImmunoTech Inc., listed on the NYSE American as AIM, is undertaking this collaboration to advance their research efforts in this critical area of oncology.